Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-4-C3HPG is a synthetic, stereoselective agonist/antagonist ligand for group I metabotropic glutamate receptors (mGluRs), especially the mGluR1 and mGluR5 subtypes. Its core structure is a phenylglycine derivative, and it acts as a **selective group I mGluR antagonist**, with moderate agonist properties as well. It is primarily used in research to study the function of mGluR1 and mGluR5 in the central nervous system. Analogs such as (R,S)-4C3HPG or other stereoisomers may have different receptor profiles. (S)-4-C3HPG is not approved for therapeutic use and is used exclusively in experimental and preclinical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-4-C3HPG.